T C Wu

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice
    T C Wu
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21287, USA
    J Virol Methods 65:287-98. 1997
  2. ncbi request reprint Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 171:2970-6. 2003
  3. pmc Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Hum Gene Ther 16:584-93. 2005
  4. ncbi request reprint Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
    Chia Jung Hsieh
    Department of Pathology, The Johns Hopkins University School of Medicine, Richard Ross Research Building, Baltimore, MD 21205, USA
    Vaccine 22:3993-4001. 2004
  5. ncbi request reprint Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
    C F Hung
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer Res 61:1080-8. 2001
  6. pmc Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice
    S Peng
    Department of Pathology, The Johns Hopkins University School of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 13:67-77. 2006
  7. pmc Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 15:677-87. 2008
  8. ncbi request reprint Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe
    Cornelia Trimble
    Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institution, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Vaccine 21:4036-42. 2003
  9. ncbi request reprint Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Res 65:309-16. 2005
  10. pmc Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 180:7019-27. 2008

Detail Information

Publications91

  1. ncbi request reprint Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice
    T C Wu
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21287, USA
    J Virol Methods 65:287-98. 1997
    ..This experimental model provides a potential system for studying the molecular pathogenesis of HPV infections...
  2. ncbi request reprint Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 171:2970-6. 2003
    ..Therefore, DNA vaccines that combine strategies to enhance intracellular Ag processing and prolong DC life have potential clinical implications for control of viral infection and neoplasia...
  3. pmc Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Hum Gene Ther 16:584-93. 2005
    ..Our data indicate that transfection of dendritic cells with BAK/BAX siRNA represents a plausible strategy for enhancing dendritic cell-based vaccine potency...
  4. ncbi request reprint Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
    Chia Jung Hsieh
    Department of Pathology, The Johns Hopkins University School of Medicine, Richard Ross Research Building, Baltimore, MD 21205, USA
    Vaccine 22:3993-4001. 2004
    ..Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy...
  5. ncbi request reprint Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
    C F Hung
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer Res 61:1080-8. 2001
    ..These results indicate that fusion of a gene encoding the extracellular domain of FL to an antigen gene may greatly enhance the potency of DNA vaccines via CD8-dependent pathways...
  6. pmc Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice
    S Peng
    Department of Pathology, The Johns Hopkins University School of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 13:67-77. 2006
    ..These results highlight the importance of epitope immunodominance in the evaluation of immune responses in HLA-A2 (AAD) transgenic mice...
  7. pmc Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 15:677-87. 2008
    ....
  8. ncbi request reprint Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe
    Cornelia Trimble
    Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institution, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Vaccine 21:4036-42. 2003
    ..m.) and biojector administrations. Thus, our data suggest that DNA vaccination via gene gun represents the most potent regimen for DNA administration...
  9. ncbi request reprint Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Res 65:309-16. 2005
    ....
  10. pmc Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 180:7019-27. 2008
    ..Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting...
  11. ncbi request reprint Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen
    C F Hung
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 61:3698-703. 2001
    ..These results indicate that fusion of the translocation domain of a bacterial toxin to an antigen may greatly enhance vaccine potency...
  12. ncbi request reprint Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene
    W F Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 166:6218-26. 2001
    ..This antitumor effect was dependent on NK cells and CD8(+) T cells. These results indicated that fusion of HSP70 to an Ag gene may greatly enhance the potency of self-replicating RNA vaccines...
  13. ncbi request reprint CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination
    W F Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 10:1311-20. 2003
    ....
  14. pmc Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6
    Shiwen Peng
    Department of Pathology, Johns Hopkins University School of Medicine, Ross 512H, 720 Rutland Ave, Baltimore, MD 21205, USA
    J Virol 78:8468-76. 2004
    ..Thus, our data indicate that E6 aa48-57 contains the immunodominant epitope and that a CRT/E6 DNA vaccine may be useful for control of HPV infection and HPV-associated lesions...
  15. ncbi request reprint Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen
    C F Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 166:5733-40. 2001
    ..Our data indicated that the potency of DNA vaccines may be dramatically improved through intercellular spreading and enhanced MHC class I presentation of Ag...
  16. pmc Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen
    W F Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Virol 75:2368-76. 2001
    ..These results indicate that fusion of VP22 to an antigen gene may greatly enhance the potency of RNA replicon vaccines...
  17. pmc Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Gene Ther 18:1129-39. 2007
    ....
  18. pmc Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope
    C H Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 12:1180-6. 2005
    ..Our data indicate that a DNA vaccine encoding a SCT can lead to stable enhanced MHC class I presentation of encoded antigenic peptide and may be useful for improving DNA vaccine potency to control tumors or infectious diseases...
  19. pmc Control of human mesothelin-expressing tumors by DNA vaccines
    C L Chang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:1189-98. 2007
    ..Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity...
  20. ncbi request reprint Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, JHU School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Hum Gene Ther 15:167-77. 2004
    ..Thus, administration of DNA encoding VP22 linked to antigen represents a plausible approach for the development of protective DNA vaccines...
  21. pmc DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency
    Chien Fu Hung
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Ther 15:1211-9. 2007
    ..Therefore, this strategy may be expected to have significant potential for clinical translation...
  22. pmc Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination
    Chih Wen Tseng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:3185-92. 2008
    ....
  23. pmc Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 15:1176-83. 2008
    ..The clinical implications of the current study are discussed...
  24. pmc Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Invest 112:109-17. 2003
    ..Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency...
  25. pmc A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects
    S Peng
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 13:257-65. 2006
    ....
  26. pmc Generation and characterization of a preventive and therapeutic HPV DNA vaccine
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Vaccine 26:351-60. 2008
    ..Thus, the hCRTE6E7L2 DNA vaccines are capable of generating potent preventive and therapeutic effects in vaccinated mice. Our data has significant clinical implications...
  27. ncbi request reprint Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion
    Wen Fang Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Hum Gene Ther 13:553-68. 2002
    ..Our results indicated that the VP22 strategy used in the context of SIN replicon particles may facilitate the generation of a highly effective vaccine for widespread immunization...
  28. ncbi request reprint Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 64:400-5. 2004
    ..Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia...
  29. ncbi request reprint Comparison of HPV DNA vaccines employing intracellular targeting strategies
    J W Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 11:1011-8. 2004
    ..Our data suggest that the DNA vaccine linking CRT to E7 (CRT/E7) may be a suitable candidate for human trials for the control of HPV infections and HPV-associated lesions...
  30. pmc Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Virol 78:4638-45. 2004
    ..These results show that a DNA vaccine encoding CRT linked to a SARS-CoV antigen is capable of generating strong N-specific humoral and cellular immunity and may potentially be useful for control of infection with SARS-CoV...
  31. pmc Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells
    C F Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:921-9. 2007
    ....
  32. pmc Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen
    Chien Fu Hung
    Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Virol 76:2676-82. 2002
    ..These results suggested that the development of vaccines encoding VP22 fused to a target antigen might be a promising strategy for improving DNA vaccine potency...
  33. pmc Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects
    Chih Wen Tseng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 26:4314-9. 2008
    ..Our findings serve as an important foundation for future clinical translation...
  34. ncbi request reprint Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death
    T W Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 11:336-42. 2004
    ..These results suggest that strategies to delay suicidal DNA-induced cell death using antiapoptotic proteins may greatly enhance the potency of suicidal DNA...
  35. pmc Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70
    Chih Long Chang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 67:10047-57. 2007
    ..Thus, the use of Hsp70-secreting ovarian tumor cells represents a potentially effective therapy for the control of lethal ovarian cancer...
  36. pmc Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans
    Jesse Rowley
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 181:8237-47. 2008
    ....
  37. ncbi request reprint A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 11:493-9. 2004
    ....
  38. pmc Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency
    Chih Ping Mao
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    J Virol 84:2331-9. 2010
    ..Thus, the incorporation of FMGs into DNA vaccines holds promise for the successful control of viral infections and cancers in the clinic...
  39. pmc Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
    Tae Heung Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Cancer Res 73:2493-504. 2013
    ..From this conceptual base, we developed a simple approach to cancer therapy combining chemotherapy and vaccination that may be widely applicable...
  40. ncbi request reprint Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
    C H Chen
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 8:128-38. 2001
    ..Our findings suggested that DNA vaccines may provide better tumor protection than vaccinia vaccines employing the same gene, which may have implications in the future design of antigen-specific cancer immunotherapy...
  41. ncbi request reprint Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 63:2393-8. 2003
    ..Our data suggest that the centrosome may be an important locus for MHC class I antigen processing and that targeting antigen to the centrosome can improve DNA vaccine potency...
  42. ncbi request reprint Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects
    Wen Fang Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Biomed Sci 9:675-87. 2002
    ..These results have important clinical implications for the use of naked DNA vaccines in cancer immunotherapy...
  43. ncbi request reprint A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Vaccine 25:127-35. 2007
    ....
  44. ncbi request reprint Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 12:689-700. 2005
    ..Our data indicate that all of the intracellular targeting and intercellular spreading strategies that have been shown to enhance E7 DNA vaccine potency were also able to enhance E6 DNA vaccine potency...
  45. pmc Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 25:7824-31. 2007
    ..Furthermore, we show that mice treated with SCT-E6 and Bcl-xL DNA generated enhanced anti-tumor effects against E6-expressing tumor cells (TC-1/Luciferase) compared to mice treated with SCT-E6 and mtBcl-xL DNA...
  46. ncbi request reprint Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen
    K F Hsu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 8:376-83. 2001
    ..The antitumor effect was predominantly CD8-dependent. These results indicate that linkage of Hsp70 to the antigen may greatly enhance the potency of suicidal DNA vaccines...
  47. pmc Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects
    S Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 15:1156-66. 2008
    ..Thus, our study has significant potential for future clinical translation...
  48. ncbi request reprint Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Gene Ther 18:575-88. 2007
    ....
  49. pmc Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
    Sung Yong Lee
    Department of Pathology, Johns Hopkins Medical Institutions, CRB II Room 309, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Immunol Immunother 62:1175-85. 2013
    ..Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer...
  50. pmc Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts
    Chih Wen Tseng
    Department of Pathology, The Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Immunol Immunother 58:737-48. 2009
    ..The clinical implications of the study are discussed...
  51. pmc Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA
    T H Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 17:531-40. 2010
    ....
  52. pmc Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
    Ken Yu Lin
    Department of Pathology, Institute of Genetic Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:1832-41. 2007
    ..These data provide evidence that tumor expression of VCAM-1 represents a new mechanism of immune evasion and has important implications for the development of immunotherapy for human RCC...
  53. ncbi request reprint Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice
    C F Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:20-9. 2007
    ..Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers...
  54. pmc RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 19:763-73. 2008
    ..Thus, intradermal administration of DNA encoding shRNA represents a plausible approach to silence genes in vivo and a potentially useful tool to enhance DNA vaccine potency...
  55. pmc Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
    Chi Mu Chuang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 17:32. 2010
    ..The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer...
  56. pmc Innovative DNA vaccine to break immune tolerance against tumor self-antigen
    Tae Heung Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Gene Ther 24:181-8. 2013
    ..Such strategy may be used in other antigenic systems for the control of infections and/or cancers...
  57. pmc Characterization of human papillomavirus type 11-specific immune responses in a preclinical model
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Baltimore, Maryland 21287, USA
    Laryngoscope 120:504-10. 2010
    ..Therefore, we developed a novel, therapeutic DNA vaccine targeting HPV-11 and characterized the in vivo immunologic responses generated against HPV-11 E6 and E7 after DNA vaccination in a preclinical model...
  58. pmc Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy
    Yu Qian Zhang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Mol Ther 18:692-9. 2010
    ..The clinical implications of this study are discussed...
  59. pmc Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination
    Sung Yong Lee
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Mol Med (Berl) 91:1221-31. 2013
    ..Both AR-42 and CRT/E7 DNA vaccines have been used in independent clinical trials; the current study serves as foundation for future clinical trials combining both treatments in cervical cancer therapy...
  60. pmc Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing
    Tae Heung Kang
    Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
    Mol Ther 21:542-53. 2013
    ..Our findings have important implications for bypassing immune tolerance to enhance cancer immunotherapy...
  61. pmc Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3
    Cornelia L Trimble
    Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 59:799-803. 2010
    ..This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation...
  62. pmc Carrageenan as an adjuvant to enhance peptide-based vaccine potency
    Yu Qian Zhang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Vaccine 28:5212-9. 2010
    ..Thus, our data suggest that CGN and its structurally related compounds may serve as innovative adjuvants for enhancing peptide-based vaccine potency...
  63. pmc DNA vaccines for cervical cancer: from bench to bedside
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Exp Mol Med 39:679-89. 2007
    ..The impressive pre- clinical data generated from our studies have led to several HPV DNA vaccine clinical trials...
  64. pmc HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:2479-87. 2007
    ..The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches...
  65. ncbi request reprint Immunotherapeutic strategies employing RNA interference technology for the control of cancers
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Biomed Sci 14:15-29. 2007
    ....
  66. pmc Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 62:171-82. 2013
    ..We recommend a single, preconditioning dose of CTX prior to vaccination due to its efficacy, ease of administration, and reduced cumulative adverse effect on vaccine-induced T cells...
  67. ncbi request reprint Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method
    C C Huang
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Mod Pathol 11:971-7. 1998
    ..We concluded that our new method was highly sensitive and could be applied to formalin-fixed, paraffin-embedded clinical material for the detection of HPV...
  68. pmc Immunological research using RNA interference technology
    Chih Ping Mao
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimire, MD 21231, USA
    Immunology 121:295-307. 2007
    ..In the present review, we examine the current progress of immunological studies employing RNAi and discuss the prospects for the implementation of this technique in the clinical arena...
  69. pmc Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors
    Chao Yi Wu
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Cancer Immunol Immunother 60:1085-96. 2011
    ..Taken together, our data indicate that PEI can potentially be used to improve the uptake of poly(I:C) by CD11b+ macrophages, leading to the activation of NK cells and the control of murine ovarian tumors...
  70. pmc Antigen-specific immunotherapy of cervical and ovarian cancer
    Chien Fu Hung
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Immunol Rev 222:43-69. 2008
    ..Here we focus on mesothelin as a promising ovarian TAA, because it is overexpressed and immunogenic at high frequency in patients, is displayed on the cell surface, and potentially contributes to ovarian cancer biology...
  71. pmc Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery
    Simon R Best
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 27:5450-9. 2009
    ..We conclude that electroporation is a promising method for delivery of HPV DNA vaccines and should be considered for DNA vaccine delivery in human clinical trials...
  72. pmc Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
    Tae Heung Kang
    Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America
    PLoS ONE 7:e35141. 2012
    ..Our approach represents a platform technology to specifically deliver proteins of interest to tumor loci...
  73. pmc Efficient delivery of DNA vaccines using human papillomavirus pseudovirions
    S Peng
    Department of Pathology, School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 17:1453-64. 2010
    ..Our data suggest that DNA vaccines delivered using HPV pseudovirions represent an efficient delivery system that can potentially affect the field of DNA vaccine delivery...
  74. pmc In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Cell Biosci 1:3. 2011
    ..MicroRNA (miRNA) molecules are potent mediators of post-transcriptional gene silencing that are emerging to be critical in the regulation of innate and adaptive immunity...
  75. pmc Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection
    Tae Heung Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Vaccine 29:1082-9. 2011
    ..The clinical implications of the study are discussed...
  76. pmc Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells
    Shaw Wei D Tsen
    Department of Pathology, John Hopkins School of Medicine, Baltimore, MD 21231, USA
    Expert Rev Vaccines 6:227-39. 2007
    ....
  77. pmc Therapeutic human papillomavirus vaccines: current clinical trials and future directions
    Chien Fu Hung
    The Johns Hopkins University School of Medicine, Department of Pathology, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, USA
    Expert Opin Biol Ther 8:421-39. 2008
    ..Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7...
  78. pmc Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
    Chih Wen Tseng
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Mol Med (Berl) 86:899-908. 2008
    ..Our data have significant implications for future clinical translation...
  79. ncbi request reprint Vaccines against human papillomavirus
    Yen Yu Lin
    Department of Pathology, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, Maryland 21287, USA
    Front Biosci 12:246-64. 2007
    ..If these prophylactic and therapeutic HPV vaccines prove as successful in patients as they have in animal models, vaccination may provide for control and eventually eradication of oncogenic HPV infection and HPV-related cancers...
  80. ncbi request reprint Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma
    M Jim Yen
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:827-31. 2006
    ..In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma...
  81. pmc Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53
    Ruey Shyang Soong
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America
    PLoS ONE 8:e56912. 2013
    ..This study showed intramuscular vaccination with xenogeneic p53 DNA vaccine followed by electroporation is capable of inducing potent antitumor effects against tumors expressing mutated p53 through CD8(+) T cells...
  82. doi request reprint Molecular epidemiology of human papillomavirus
    Talia Hoory
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    J Formos Med Assoc 107:198-217. 2008
    ....
  83. pmc Inhibitory RNA molecules in immunotherapy for cancer
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Methods Mol Biol 623:325-39. 2010
    ....
  84. pmc Femtosecond laser treatment enhances DNA transfection efficiency in vivo
    Shaw Wei D Tsen
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21218, USA
    J Biomed Sci 16:36. 2009
    ..Gene therapy with plasmid DNA is emerging as a promising strategy for the treatment of many diseases. One of the major obstacles to such therapy is the poor transfection efficiency of DNA in vivo...
  85. pmc Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
    Chao Yi Wu
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 17:88. 2010
    ..Peptide-based vaccines targeting HPV E6 and/or E7 antigens while safe, will most likely require additional strategies to enhance the vaccine potency...
  86. pmc How will HPV vaccines affect cervical cancer?
    Richard Roden
    Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Nat Rev Cancer 6:753-63. 2006
    ..Here we examine the ramifications and remaining questions that surround preventive HPV vaccines...
  87. ncbi request reprint Preventive and therapeutic HPV vaccines
    Archana Monie
    The Johns Hopkins Medical Institutions, Department of Pathology, 1550 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 8:1038-50. 2007
    ..Thus, the future of HPV vaccination needs to focus on the development of a new generation of preventive and therapeutic vaccines that are capable of protecting against most cervical cancers...
  88. pmc Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis
    Jesse Rowley
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Eur J Immunol 39:491-506. 2009
    ..The clinical implications of the current study are discussed...
  89. pmc Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 18:21. 2011
    ..In addition, we determined that inducible nitric oxide synthase (iNOS) plays a role in the immune suppression caused by DMXAA administration before DNA vaccination. Our study has significant implications for future clinical translation...
  90. ncbi request reprint Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer
    T C Wu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Eur J Immunol 37:310-4. 2007
    ..Continued exploration of HPV therapeutic DNA vaccines may lead to eventual clinical application...
  91. pmc Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer
    Chih Long Chang
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Mol Ther 17:1365-72. 2009
    ..Thus, the combination of Cox-2 inhibitors and vaccinia virus represents a potential innovative approach to controlling ovarian tumors...